# EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct06556563/  
OnCo record `nct06556563` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Temozolomide and Pembrolizumab in glioma & glioblastoma, run by NovoCure GmbH, now recruiting.

## Summary

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma is a phase 3 interventional study registered as NCT06556563 by NovoCure GmbH, with 741 participants planned, started 2025-02-03 and due to reach its primary completion in 2029-04. Interventions recorded: Optune® device, Temozolomide, Pembrolizumab and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06556563
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).
- Sponsor: NovoCure GmbH
- Enrolled: 741

## Sources

- ClinicalTrials.gov NCT06556563: https://clinicaltrials.gov/study/NCT06556563

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Novocure](https://onco.cc/companies/novocure/)

---
JSON: https://onco.cc/api/v1/entities/nct06556563.json